The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcit...
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was f...
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annua...
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentu...
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoad...
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40...
In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicente...
In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly imp...
The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, ac...
The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlle...
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall ...
In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in t...
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–muta...
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast t...
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of erib...
For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly re...
In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halt...
Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy att...
Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or ...
Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early relapse. Belantamab mafodotin is an antibody-d...
Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in...
Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradi...
As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase I...
A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, accordin...
As reported at the 2024 ASCO Annual Meeting (Abstract LBA105) and in The New England Journal of Medicine by Meletios Dimopoulos, MD, and colleagues, an interim analysis from the phase III DREAMM-8 tri...
As reported at the 2024 ASCO Annual Meeting (Abstract 7500) and in The New England Journal of Medicine by Thierry Facon, MD, and colleagues, interim analysis of the phase III IMROZ trial showed signif...
The novel therapy INB-200 in combination with concomitant temozolomide may improve survival in patients with glioblastoma multiforme, according to preliminary findings from a phase I clinical trial pr...
An integrated palliative care rotation for hematology-oncology fellows may improve their palliative care knowledge and skill confidence, according to findings presented by Bauman et al at the 2024 ASC...
Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body M...
Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential ...
Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by t...
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemora...
The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504). Backgr...
Researchers have examined whether adding chemoradiation to adjuvant systemic therapy may improve survival outcomes in patients with resected periampullary pancreatic adenocarcinoma, according to recen...
Researchers have found that about 6% of patients with non–small cell lung cancer (NSCLC) and KRAS, EGFR, or ALK gene mutations may also have HER2 alterations, according to recent findings presented by...
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients w...
Intensity-modulated proton therapy may achieve similar clinical outcomes and offer significant benefits compared with traditional intensity-modulated radiation therapy in patients with oropharyngeal c...
Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–hig...
Researchers have shown the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings published by Temel et al in JAMA and simul...
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented b...
A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy called huCART19-IL18 may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell ...
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage II...
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymp...
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, c...
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-r...
Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation ant...
Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support dara...
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic l...
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving...
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-rela...